期刊文献+

去势大鼠骨组织中OPG、VEGF在雌激素治疗前后的变化

The expression of OPG、VEGF in the bones of ovariectomized rats before and after estrogen treatment
下载PDF
导出
摘要 目的制备去卵巢大鼠骨质疏松模型,比较去势6、8周后胫骨上VEGFmRNA、OPG的表达,及雌激素治疗后的变化。方法53只6月龄的SD雌性大鼠随机分成3组:OVX组(去势组),sham组(假手术组),OVX+E:组(雌激素治疗组);分别在去势后6周末和8周末股动脉放血处死大鼠,每组各8只。取右侧胫骨脱钙后,行组织形态学观察及VEGF原位杂交和OPG免疫组化镜下观察。结果去势6周和8周后,可见:(1)OPG蛋白表达情况:030PG阳性细胞主要表达在大鼠胫骨的关节软骨细胞,骺板肥大区软骨细胞,及骺板下初级骨小梁的黏合线上。成骨细胞和骨细胞呈弱阳性表达。骨髓腔间充质细胞表达弱或没有表达,巨核细胞可有弱阳性的表达;②与sham组相比,OVX组中关节软骨细胞,骺板肥大区软骨细胞阳性表达有升高趋势;③与OVX组相比,OVX+E2组关节软骨细胞,骺板肥大区软骨细胞阳性表达有升高趋势;(2)VEGFmRNA表达情况:①VEGFmRNA阳性细胞主要表达于关节软骨细胞、骺板肥大区细胞和增生区细胞、成骨细胞和骨细胞及骨髓间充质细胞和巨核细胞、皮质外侧的成纤维细胞;②与sham组相比,OVX组骺板肥大区软骨细胞、关节软骨细胞、骨髓间充质细胞阳性表达有升高趋势;③与OVX组相比,OVX+E,组关节软骨、骺板肥大区软骨细胞阳性信号有降低趋势;骨髓间充质细胞的阳性信号有升高趋势。结论(1)去势后雌激素降低,骨重建加强,骨吸收和骨形成均增加,OPG一过性升高可调节破骨细胞的募集和形成。雌激素治疗后OPG表达增高提示OPG可能具有一定的雌激素依赖性。(2)去势后雌激素降低,VEGF生成增多,并参与到骨的血管形成过程中,参与骨丢失。VEGF可能作为破骨细胞的诱导物,促使破骨细胞形成。给予雌激素治疗后,雌激素可使VEGF参与血管形成过程,调节成骨细胞的骨形成过程。 Objective To observe the local expressions of VEGF mRNA and OPG in tibias of 6weeks,8 weeks after ovariectomized rats, and OPG,VEGF mRNA changes after E2 treatment. Methods Fifty-three female SD rats, six months, were randomly divided into 3 groups: ovx (ovariectomized) group, sham group and estrogen treatment. Every group had 8 rats. All rats were sacrificed by arteria cruralis bleeding at the end of 6 w and 8 w after ovx. We selected right tibias to observe histology, in situ hybridization of VEGF mRNA and immunohistochemistry of OPG and counted. Results 6 w and 8 w after ovx, we can see (1)OPG protein expression expressions: (1)OPG protein expressions are mainly situated in cartilar cartilage cells, hypertrophic chondrocytes of epiphyseal plate, and cement line of primary bone trabecula. Osteoblasts and osteocytes are weakly positive. Mesenchymal ceils in bone marrow expressed very weak or no. And megakaryocytes are weakly positive; (2) In ovx groups, OPG protein expressions in cartilar cartilage cells, hypertrophic chondrocytes of epiphyseal plate have a more tendency than those of sham groups;(1)In ovx + E2 groups, OPG protein expressions in above locations have a more tendency than those of ovx groups; (2)VEGF mRNA expressions status:(1)VEGF mRNA expressions are mostly situated in cartilar cartilage cells, hypertrophic chondroeytes and proliferative chondrocytes of epiphyseal plate, osteoblasts, osteocytes, and mesenchymal cells in bone marrows, especially megakaryocytes, and fibroblasts besides cortical substances; (2)In ovx groups VEGF mRNA expressions in cartilar cartilage cells, hypertrophic chondrocytes of epiphyseal plate and mesenchymal cells in bone marrow have a more tendency than those of sham groups; (3)In ovx + E2 goups VEGF mRNA expressions in cartilar cartilage cells, hypertrophic chondrocytes of epiphyseal plate have a less tendency than those of ovx groups. Conclusion (1)After ovx, estrogen defect, which makes both bone remodeling strong and bone rosorption and formation enhancing, may result in a increasing moment expression of OPG to accommodate osteoclast recruitment and formation; Afer estrogen treatment, the increasing expression of OPG may indicate OPG has partly an estrogen-dependency. (2) Estrogen defect after ovx may produce more VEGF to participate in bone angiopoietic process. And perhaps more angiopoiesis formate to participate in bone loss. Moreover, VEGF as osteoclasic chemotaxin may induce osteoclast bone resorption. Mer estrogen treatment, estrogen stimulate VEGF to participate in bone angiopoietic process so as to regulate bone formation by osteoblast.
出处 《中国骨质疏松杂志》 CAS CSCD 2009年第8期551-556,共6页 Chinese Journal of Osteoporosis
基金 天津市自然科学基金资助项目(003606711)
关键词 OPG VEGF 骨质疏松 去势 成骨细胞 破骨细胞 骺板 软骨细胞 Osteporotegerin Vascular endothelial growth factor Osteoporosis Ovariectomized Osteoblast Osteoclast Epiphyseal plate Chondrocyte
  • 相关文献

参考文献1

二级参考文献9

  • 1Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell, 1997,89:309-319.
  • 2Takahashi N, Udagawa N, Suda T. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Biochem Biophys Res Commun, 1999, 256:449-455.
  • 3Emery JG, McDonnell P, Burke MB, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem, 1998, 273:14363-14367.
  • 4Sumbrook J. Molecular cloning laboratory manual. 2nd ed. New York: Cold Spring Harbor laboratory Press, 1989. 345-897.
  • 5Turner RT, Riggs BL, Spelsberg TC. Skeletal effects of estrogen. Endocr Rev, 1994, 15: 275-300.
  • 6Hofbauer LC, Khosla S, Dunstan CR, et al. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology, 1999, 140:4367-4370.
  • 7Atkins G, Haynes DR, Graves SE, et al. Expression of osteoclast differentiation signals by stromal elements of giant cell tumors. J Bone Miner Res, 2000, 15: 640-649.
  • 8Murakami T, Yamamoto M, Ono K, et al. Transforming growth factor-beta1 increases mRNA levels of osteoclastogenesis inhibitory factor in osteoblastic/stromal cells and inhibits the survival of murine osteoclast-like cells. Biochem Biophys Res Commun, 1998, 252:747-752.
  • 9Sibonga JD, Dobnig H, Harden RM, et al. Effect of the high-affinity estrogen receptor ligand ICI182,780 on the rat tibia. Endocrinology, 1998,139:3736-3742.

共引文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部